Immunome's IM-1021 shows 53% response rate in early-stage B-cell lymphoma trial

• Immunome will present initial Phase 1 results for IM-1021 in advanced B-cell lymphomas at ASH on December 14, 2026.
• The experimental antibody-drug conjugate produced complete and partial responses in heavily pretreated patients, with responses across all tested dose levels.
• Clinical activity included patients whose disease had progressed following T-cell redirecting therapies.
• Serious treatment-emergent adverse events included low neutrophil counts, the most common severe event.
• Dose optimization across multiple regimens remains ongoing, with updated results planned for the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104589966) on November 04, 2026, and is solely responsible for the information contained therein.